| abstract |
This invention relates to certain carbamic acid compounds that inhibit HDAC (histone deacetylase) activity of the following formula: (see formula 1) wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or a cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or -C (= O) -; J2 is independently -C (= O) - or -S (= O) 2 -; Q2 is independently a leading acid group; wherein: Cy is independently: C3-20 carbocyclyl; C3-20 heterocyclyl; or C5-20 aryl; and is optionally substituted; Q1 is independently: a covalent bond; C1-7 alkylene or C1-7-X alkylene C1-7 alkylene or C1-7-X alkylene, wherein X is -O- or -s-; and is optionally substituted; Q2 is independently: C4-8 alkylene; and is optionally substituted; and has a base structure length of at least four atoms; or: Q2 is independently: C5-20 arylene-C1-7 alkylene; C1-7-C5-20 alkylene alkylene or C1-7-arylene alkylene of C5-20-C1-7 alkylene; and is optionally substituted; and has a base structure length of at least four atoms; or a salt, solvate, amide, ester, ether, chemically protected form or pharmaceutically acceptable prodrugs thereof. The present invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis. , etc. |